Nucleic acid capable of inhibiting expression of beta-2gpi
AssigneeKyowa Hakko Kirin Co., Ltd.
InventorsYoji YAMADA, Hiroto IWAI, Kazuhiro MASUDA, Minako KANDA
Life of this patent
Estimating the term…
Abstract
The present invention provides a nucleic acid having activity to suppress expression of β2GPI, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.
Claims10
A method of treating a disorder mediated by an anti-β2GPI antibody, comprising a step of administering a therapeutically effective amount of a double-stranded nucleic acid that decreases expression of β2GPI gene or a pharmaceutical composition comprising the double-stranded nucleic acid to a human in need of such treatment, wherein the double-stranded nucleic acid consists of a sense strand and an antisense strand, and comprises a double-stranded region of at least 11 base pairs, wherein an oligonucleotide chain having a chain length of at least 17 nucleotides and nucleotides at most in the aforementioned antisense strand is complementary to a target β2GPI mRNA sequence selected from the group described in Tables 1-1 to 1-16.
Dependencies are inferred from the claim text.